MiNK Therapeutics, Inc.
INKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $15 | $23 | $14 |
| G&A Expenses | $4,314 | $7 | $0 | $0 |
| SG&A Expenses | $4 | $7 | $8 | $5 |
| Sales & Mktg Exp. | -$4,310 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $10 | $23 | $31 | $19 |
| Operating Income | -$11 | -$23 | -$31 | -$19 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $0 | $3 | -$12 |
| Pre-Tax Income | -$11 | -$22 | -$28 | -$30 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$22 | -$28 | -$30 |
| % Margin | – | – | – | – |
| EPS | -2.9 | -6.54 | -8.31 | -9.03 |
| % Growth | 55.7% | 21.3% | 8% | – |
| EPS Diluted | -2.8 | -6.54 | -8.31 | -9.03 |
| Weighted Avg Shares Out | 4 | 3 | 3 | 3 |
| Weighted Avg Shares Out Dil | 4 | 3 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$22 | -$28 | -$28 |
| % Margin | – | – | – | – |